DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Down 8.4% in January

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) was the recipient of a significant decline in short interest in January. As of January 31st, there was short interest totalling 191,900 shares, a decline of 8.4% from the January 15th total of 209,500 shares. Based on an average daily trading volume, of 103,200 shares, the days-to-cover ratio is currently 1.9 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of DiaMedica Therapeutics in a research report on Friday, November 15th.

Institutional Investors Weigh In On DiaMedica Therapeutics

Several large investors have recently made changes to their positions in DMAC. Point72 Asia Singapore Pte. Ltd. acquired a new position in DiaMedica Therapeutics during the third quarter worth $40,000. Balyasny Asset Management L.P. acquired a new position in DiaMedica Therapeutics during the fourth quarter worth $79,000. Y Intercept Hong Kong Ltd acquired a new position in DiaMedica Therapeutics during the fourth quarter worth $81,000. Raymond James Financial Inc. acquired a new position in DiaMedica Therapeutics during the fourth quarter worth $83,000. Finally, Bank of Montreal Can acquired a new position in DiaMedica Therapeutics during the fourth quarter worth $84,000. Institutional investors own 10.12% of the company’s stock.

DiaMedica Therapeutics Price Performance

Shares of DMAC stock opened at $6.16 on Wednesday. The firm has a fifty day moving average of $5.70 and a 200-day moving average of $4.77. DiaMedica Therapeutics has a 12-month low of $2.14 and a 12-month high of $6.45.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.